U.S. pharmaceutical giant Eli Lilly and Company has announced plans to invest about $3 billion in China over the next ten years, strengthening its manufacturing and supply chain presence in one of the world’s largest healthcare markets.
The investment will focus on expanding the company’s production capacity and supply chain infrastructure in China, particularly for medicines targeting type 2 diabetes and obesity. One of the key drugs involved in the expansion is orforglipron, an experimental oral treatment currently under regulatory review in the country.
Eli Lilly said it has already submitted a marketing application for orforglipron to Chinese drug regulators in late 2025, signaling its intention to compete in the rapidly growing market for metabolic disease treatments.
The company also aims to develop a localized manufacturing and supply system for oral medicines, which would help ensure faster production and distribution for patients across China and the wider region.
China represents one of the most important global pharmaceutical markets due to its large population and rising demand for treatments related to diabetes, obesity, and chronic diseases. By expanding its investment there, Eli Lilly hopes to strengthen its position against other global drugmakers competing in the same therapeutic areas.
Industry analysts say the move reflects the growing strategic importance of China for major pharmaceutical companies seeking to expand manufacturing capacity, accelerate drug approvals, and capture long term growth in the global healthcare sector.
Leave a comment